Eye Health News and Research

Latest Eye Health News and Research

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

A comprehensive drug development strategy that starts with extensive screening of potential targeting agents and then narrows down to a small-molecule prototype has yielded two potential drugs that block cancer-promoting pathways in novel ways, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in two papers published back-to-back online at the Proceedings of the National Academies of Science.

26 Feb 2010

CPM procedure may only offer survival benefit to breast cancer patients age 50 and younger

Contralateral prophylactic mastectomy (CPM), a preventive procedure to remove the unaffected breast in patients with disease in one breast, may only offer a survival benefit to breast cancer patients age 50 and younger, who have early-stage disease and are estrogen receptor (ER) negative, according to researchers at The University of Texas M. D. Anderson Cancer Center.

26 Feb 2010

Researchers keep wary eye on emerging tick-borne diseases in Missouri

Stories of environmental damage and their consequences always seem to take place far away and in another country, usually a tropical one with lush rainforests and poison dart frogs.

26 Feb 2010

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to 4,000 people, or 1.5 million people worldwide.

25 Feb 2010

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say.

25 Feb 2010

A bird's-eye view of health overhaul lobbying

The Center for Public Integrity's new "analysis of Senate lobbying disclosure forms shows that more than 1,750 companies and organizations hired about 4,525 lobbyists — eight for each member of Congress — to influence health reform bills in 2009."

24 Feb 2010

Muscle Flex changes name to Bravada International

Muscle Flex Inc. announced today that in it will be changing its name to Bravada International Ltd., a name that more accurately reflects the company's growing depth of its business affairs. Muscle Flex® will remain an integral part of the company as the health and fitness product and services brand.

24 Feb 2010

NanoViricides files quarterly report with Securities and Exchange Commission

NanoViricides, Inc. has filed its quarterly report with the Securities and Exchange Commission yesterday in a timely fashion.

24 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

ExonHit Therapeutics includes proprietary lead compounds into collaboration with Allergan

ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.

23 Feb 2010

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

When head and neck tumors - from sinus tumors to acoustic neuromas attached to the hearing and balance nerve at the base of the skull - are located in close proximity to such sensitive areas such as the brain and eyes, they are particularly dangerous due to possible brain injury, visionary risk or hearing loss.

23 Feb 2010

Medicaid cuts hurt Calif. dental coverage, drive away doctors in Okla; Public hospitals in NYC fear possible reductions

NPR: "In California, it's been seven months since some 3 million poor and disabled adults lost their dental coverage to budget cuts. ... While the recession may be easing, California and other states across the country continue to face eye-popping budget deficits. As a result, states are cutting deep into public health programs, and dental benefits for Medicaid recipients top the list. ... Before the state budget cuts, Medicaid patients here could get annual exams, cleanings and, if needed, root canals to save their teeth.

23 Feb 2010

DSAEK cornea transplant offers potential long-term benefits

One year post-surgery, patients who underwent Descemet's stripping automated endothelial keratoplasty experienced greater cell loss overall compared to those who underwent penetrating keratoplasty, according to a new analysis of data collected from the Cornea Donor Study Investigator Group's 2008 Specular Microscopy Ancillary Study.

23 Feb 2010

Siestas can dramatically boost and restore brain power

If you see a student dozing in the library or a co-worker catching 40 winks in her cubicle, don't roll your eyes. New research from the University of California, Berkeley, shows that an hour's nap can dramatically boost and restore your brain power. Indeed, the findings suggest that a biphasic sleep schedule not only refreshes the mind, but can make you smarter.

21 Feb 2010

Study: Elderly people with untreated visual disorders more likely to develop Alzheimer's disease

Elderly people with visual disorders that are left untreated are significantly more likely to develop Alzheimer's disease -- the most common form of dementia, according to a University of Michigan Health System study.

19 Feb 2010

Valensa International enters into license agreement with Biova for BiovaFlex ingredient

Valensa International (Eustis, FL USA) announced today that it has entered into a license agreement with Biova, LLC (Johnston, Iowa USA) that will allow Valensa to include the patented BiovaFlex(TM) water-soluble egg shell membrane ingredient in a proprietary new series of formulated joint health products.

19 Feb 2010

Report: Green tea catechins may protect against glaucoma and other common eye diseases

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

19 Feb 2010

Epeius Biotechnologies completes construction of VPU to manufacture targeted genetic medicines

Epeius Biotechnologies (www.epeiusbiotech.com) announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in GMP, CMC, aseptic processing, and quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century.

18 Feb 2010

OPKO Health acquires Pharmacos Exakta

OPKO Health, Inc. today announced that it has completed the acquisition of Pharmacos Exakta, S.A. de C.V. (“Pharmacos Exakta”), a privately-owned Mexican pharmaceutical company engaged in the manufacture, marketing and distribution of ophthalmic and other pharmaceutical products for government and private markets since 1957. OPKO acquired Pharmacos Exakta, including a manufacturing facility owned by an affiliate, for cash and shares of OPKO Common Stock.

18 Feb 2010

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare AG announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME).

18 Feb 2010

Eye Health News and Research

Latest Eye Health News and Research

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

CPM procedure may only offer survival benefit to breast cancer patients age 50 and younger

Researchers keep wary eye on emerging tick-borne diseases in Missouri

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

A bird's-eye view of health overhaul lobbying

Muscle Flex changes name to Bravada International

NanoViricides files quarterly report with Securities and Exchange Commission

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

ExonHit Therapeutics includes proprietary lead compounds into collaboration with Allergan

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

Medicaid cuts hurt Calif. dental coverage, drive away doctors in Okla; Public hospitals in NYC fear possible reductions

DSAEK cornea transplant offers potential long-term benefits

Siestas can dramatically boost and restore brain power

Study: Elderly people with untreated visual disorders more likely to develop Alzheimer's disease

Valensa International enters into license agreement with Biova for BiovaFlex ingredient

Report: Green tea catechins may protect against glaucoma and other common eye diseases

Epeius Biotechnologies completes construction of VPU to manufacture targeted genetic medicines

OPKO Health acquires Pharmacos Exakta

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Genetics & Genomics - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in